People who took tesamorelin felt better about how their belly looked, and doctors also thought their belly looked better — even though their outer fat didn’t change, just the inside fat.
Scientific Claim
Tesamorelin (2 mg subcutaneous daily) causes significant improvements in patient-reported belly appearance distress and physician-rated belly profile in HIV-infected adults with central fat accumulation over 6 months, independent of changes in subcutaneous fat.
Original Statement
“Patient rating of belly appearance distress (P = 0.02) and physician rating of belly profile (P = 0.02) were significantly improved in the tesamorelin vs. placebo-treated groups.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The RCT design with blinded assessments and significant P-values supports definitive causal language. The claim accurately reflects the reported outcomes without overgeneralization.
Evidence from Studies
Supporting (1)
The study found that a daily shot of tesamorelin helped HIV patients feel better about their belly appearance and made their belly look better to doctors — without changing the fat under the skin, just the deep belly fat.